| Cell Type |
Source/Route |
Animal Model |
Findings |
Reference |
| ELPC and eNOS transduced ELPCs |
Bone marrow / IV |
MCT |
When administered 3 days after MCT induced PAH - complete prevention of PAH
3 weeks after injury – prevented further increase in RVSP
ENOS transduced ELPCs - normalized pulmonary hemodynamics and improved survival |
Zhao, 2005 – PMID 15692087 |
| Adrenomedullin gene- transduced EPCs |
Umbilical cord blood/IV |
MCT |
Decrease in PVR and mean PAP, inhibition of increase in medial wall thickness |
Nagaya, 2003 – PMID 12835224 |
| EPC |
Peripheral blood, culture media/ injection directly into lung parenchyma |
MCT |
EPC transplantation in lungs improved mean PAH, arterial pressure, CO, PVR and improved neovascularization |
Takahashi, 2004 – PMID15265294 |
| CGRP transfected EPCs |
Peripheral blood/IV |
Shunt operation – abdominal aorta to IVC |
Decreased PAH and vascular remodeling |
Zhao Q, 2007 – PMID17643632 |
| EPCs |
Peripheral blood/IV |
Clinical study |
Increase in mean distance walked in 6 mins and improvement in mean PAP, PVR and CO |
Wang XX, 2007 – PMID17418297 |
| Prostacyclin synthase-MSCs |
Bone marrow/IV |
MCT |
Improved PH and pulmonary arteriolar remodeling and decreased RVH |
Takemiya, 2009 – PMID 19838762 |
| MSC |
Bone marrow/IV |
MCT |
Improved right ventricular function, decreased right ventricular peak systolic pressure, pulmonary artery narrowing, alveolar septum thickening and RVH |
Umar, 2009 – PMID19783775 |
| MSC
MSC
MSC |
Bone marrow
/Intratracheal
Bone Marrow
Bone Marrow |
MCT
Hyperoxia (95% O2)
Hyperoxia (75% O2) |
Improved endothelium- dependent responses and decreased pulmonary arterial resistance and PVR
Attenuated alveolar and vascular lung injury and pulmonary hypertension in neonatal rats
Reduced alveolar loss and prevented pulmonary hypertension in neonatal mice |
Baber, 2006 – PMID 16980338
Van Haaften, 2009 – PMID 19713449
Aslam M, 2009 – PMID 19713447 |
| eNOS expressing MSCs |
Bone marrow/IV |
MCT |
Improvement in right ventricular impairment, decrease in RVSP, RV/body weight ratio decreased |
Kanki-Horimoto, 2006 – PMID 16820570 |
| MSC expressing HO-1 transgene |
Bone marrow/IV |
Chronic hypoxia |
Prevented and reversed PAH, reversed RV hypertrophy and vascular remodeling.
HO-1 prevented against oxidative damage |
Liang, 2011 – PMID20957739 |
